Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials

被引：0
|
作者：
Folprecht, G.
Seymour, M. T.
Saltz, L.
Douillard, J. Y.
Stephens, R. J.
Van Cutsem, E.
Rougier, P.
Maughan, T. S.
Koehne, C. H.
机构：
[1] Univ Hosp Dresden, Dresden, Germany
[2] Cookridge Hosp, Leeds, W Yorkshire, England
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Ctr R Gauducheau, Nantes, France
[5] MRC Clin Trials Unit, London, England
[6] Univ Hosp Gasthuisberg, Leuven, Belgium
[7] Hop Ambroise Pare, Boulogne, France
[8] Velindre Hosp, Cardiff, S Glam, Wales
[9] Klinikum Oldenburg GGmbH, Oldenburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4071
引用
收藏
页数：2
相关论文
共 50 条
  • [41] QUALITY-OF-LIFE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER RECEIVING CHEMOTHERAPY - A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING 5-FU VERSUS 5-FU WITH LEUCOVORIN
    SULLIVAN, BA
    MCKINNIS, R
    LAUFMAN, LR
    PHARMACOTHERAPY, 1995, 15 (05): : 600 - 607
  • [42] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [43] Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts)
    Roth, A. D.
    Tejpar, S.
    Yan, P.
    Fiocca, R.
    Dietrich, D.
    Bodoky, G.
    Labianca, R.
    Cunningham, D.
    Van Cutsem, E.
    Bosman, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC)
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezael
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Kim, Jin Won
    Suh, Koung Jin
    Kim, Ji-Won
    Park, Jin Hyun
    Kim, Ki Hwan
    Kim, Yu Jung
    Kim, Jin-Soo
    Kim, Jee Hyun
    Choi, In Sil
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
    Glenjen, Nils
    Hammerling, Katrin
    Hatlevoll, Ingunn
    Smaland, Rune
    Hauge, Petra Weber
    Eide, Geir Egil
    Sorbye, Halfdan
    Dahl, Olav
    Frykholm, Gunilla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis.
    Mass, RD
    Fyfe, G
    Hambleton, J
    Kabbinavar, F
    Hurwitz, H
    Novotny, N
    Sarkar, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 273S - 273S
  • [48] Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
    Gamelin, EC
    DanquechinDorval, EM
    Dumesnil, YF
    Maillart, PJ
    Goudier, MJ
    Burtin, PC
    Delva, RG
    Lortholary, AH
    Gesta, PH
    Larra, FG
    CANCER, 1996, 77 (03) : 441 - 451
  • [49] 5-Fluorouracil (5-FU) plus folinic acid (FA) for patients with advanced colorectal cancer (ACRC) treated outside clinical trials
    Segura, A
    Aparicio, J
    Garcera, S
    Reynes, G
    Montalar, J
    Santaballa, A
    Yuste, A
    Herranz, C
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [50] Irinotecan (Iri) in combination with CDDP (C) or with 5-FU and folinic acid (FU/FA) is active in patients (pts) with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).
    Pozzo, C
    Szanto, J
    Peschel, C
    Popiela, T
    Gorbunova, V
    Zuber, E
    Di-Betta, D
    Alakl, M
    Jacques, C
    Barone, C
    ANNALS OF ONCOLOGY, 2000, 11 : 63 - 63
12345